Web6 jun. 2024 · The improved performance will be driven by advances made by the Ionis core antisense program. Today, we have medicines that can be administered … Web11 mei 2024 · 1 Core Antisense Research Ionis Pharmaceuticals, Inc, Carlsbad, CA 92008, USA. PMID: 35664704 PMCID: PMC9136273 DOI: 10.1016/j.omtn.2024.05.024 …
The Combination of Mesyl-Phosphoramidate Inter-Nucleotide …
WebSr. Research Associate(Core Antisense) at Ionis Pharmaceuticals, Inc. San Diego, California, United States. 101 followers 99 connections. Join to view profile ... WebAntisense oligonucleotides modified with phosphorothioate linkages (PS-ASOs) can enter cells via endocytic pathways and must escape from membraned organelles to … inclusion\\u0027s kr
Ionis
Web10 jul. 2024 · Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by loss of function of the maternally inherited UBE3A allele. In neurons, the paternal allele of UBE3A is silenced in cis by the long noncoding RNA, UBE3A-ATS . Unsilencing paternal UBE3A by reducing UBE3A-ATS is a promising therapeutic approach for the treatment of … Web1 jun. 2024 · During the virtual American Association for Cancer Research Annual Meeting 2024, held April 10–15, MacLeod presented preclinical findings on ION537. To develop the drug, his team first did pilot in vivo studies showing that subcutaneously injected ASOs depleting YAP1 in two mouse models of HCC caused tumor regression and increased … Web17 dec. 2024 · About Ionis Pharmaceuticals, Inc. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug … inclusion\\u0027s kv